摘要
肾细胞癌(renal cell carcinoma, RCC)是一种致命的恶性肿瘤,其治疗方式包括手术切除、靶向治疗、免疫治疗和联合治疗等。近年来,随着分子生物学和药物研发技术的不断发展,肾细胞癌的药物治疗取得了长足的进展,包括靶向治疗药物的不断更新、免疫治疗的革命性突破以及联合治疗的策略优化。该文将对肾细胞癌的靶向治疗、免疫治疗以及联合治疗进行系统综述。
Renal cell carcinoma(RCC)is a fatal malignant tumor that is treated by various approaches,including surgical resection,targeted therapy,immunotherapy,and combined therapy.In recent years,with the continuous development of molecular biology and drug development technology,significant progress has been made in the drug therapy of renal cell carcinoma,including the constant updating of targeted drugs,the revolutionary breakthroughs in immunotherapy,and the optimization strategies for combination therapy.This article systematically summarizes the progress in targeted therapy,immunotherapy,and combination therapy for renal cell carcinoma.
作者
黄思思
吴建辉
HUANG Sisi;WU Jianhui(School of Pharmacy,Fudan University,Shanghai 201203,China;Institute for Biomedical and Pharmaceutical Technologies,Shanghai 200032,China;NHC Key Laboratory of Reproduction Regulation,Shanghai 200032,China;Shanghai Engineering Research Center of Reproductive Health Drug and Devices,Shanghai 200032,China;Shanghai-MOST Key Laboratory of Health and Disease Genomics,Shanghai 200032,China)
出处
《现代肿瘤医学》
CAS
2024年第12期2298-2303,共6页
Journal of Modern Oncology
基金
上海市自然科学基金项目(编号:19ZR1444400)。
关键词
肾细胞癌
靶向治疗
免疫治疗
联合治疗
renal cell carcinoma
targeted therapy
immunotherapy
combination therapy
